Bulletin
Investor Alert

New York Markets Open in:

Inhibikase Therapeutics

IPO: US:IKT

Company Description

Clinical stage biotech developing kinase inhibitors for Parkinson's and related disorders.

Filing Information

File Date

7/23/2020

File Shares

2,272,727.00

Low Price Range

$10.00

High Price Range

$12.00

Proposed Offering Amount

$24,999,997

Exchange

Nasdaq

Underwriter Information

Bookrunner

ThinkEquity

Bookrunner

N/A

Bookrunner

N/A

At a Glance

Company

Inhibikase Therapeutics

Address

City/State

Atlanta, GA

Phone

N/A

Web

www.inhibikase.com

Industry

Health-Biotech

Employees

7

Founded

2008

Financial Information

Ltm Date

N/A

Ltm Sales

N/A

Employees

N/A

Use of Proceeds

Clinical trials

IPO Discussion

MarketWatch News on IKT

No news currently available
Link to MarketWatch's Slice.